Sara Tolaney: DESTINY-Breast06 – Efficacy by pace of disease progression
Sara Tolaney, Chief of the Division of Breast Oncology at Dana-Farber Cancer Institute, shared a post on X:
“DESTINY-Breast06: Efficacy by pace of disease progression.
- PFS with TDXd regardless of time to progression on 1L ET+cdk 4/6i.
- PFS2 prolonged with TDXd c/w chemo (20.3 vs 14.7mo).
- TDXd w/benefit regardless of disease burden.”
Sara Tolaney is the Chief of the Division of Breast Oncology at Dana-Farber Cancer Institute. She also serves as Associate Director of the Susan F. Smith Center for Women’s Cancers and is a Senior Physician at Dana-Farber Cancer Institute and Associate Professor of Medicine at Harvard Medical School. Her research focuses on the development of novel therapies in the treatment of breast cancer and developing more effective and less toxic treatment approaches. Her work has demonstrated that a relatively low risk regimen is beneficial in women with early stage node-negative HER2-positive cancers, and this works has been incorporated into national and international guidelines. She has developed several follow-up studies looking at novel approaches to early stage HER2-positive disease and has also played a significant role in development of cdk 4/6 inhibitors, antibody drug conjugates, and immunotherapy in breast cancer. She is the author of over 150 peer-reviewed publications in leading scientific journals. She is the recipient of the Lee M Nadler “Extra Mile” Award, and the Innovation Award for Clinical Faculty.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023